Press Release by: Ms. Sunita
03 November 2010
The European vaccines market has demonstrated growth even through tough economic times. This has mainly been due to the introduction of vaccines in untapped disease markets and government’s acceptance and willingness to pay for new products. This has encouraged market participants to increase spending in research and development.
This report, European Vaccine Markets, examines the market for vaccines used in humans for various types of disease. It covers only commercialized vaccines and developmental vaccines for diseases that are already vaccine-preventable; it does not cover emerging vaccines for diseases that are not currently vaccine-preventable, such as Alzheimer’s disease, diabetes, Ebola infection, Epstein-Barr virus (EBV) infection, ETEC infection, heart attack, Helicobacter pylori infection, multiple sclerosis, Parkinson’s disease, West Nile virus (WNV) infection, etc.; vaccines that address these conditions are discussed in Kalorama’s new report, “Emerging Vaccines: The World Market.”